BHVN

Biohaven Ltd.

$11.43 +3.81%

Recent alerts on BHVN

All signals →

SEC filing BHVN Reports Opakalim 3x Seizure Delay, 54% Responder Rate, Zero CNS AEs in Epilepsy Trials

News Why Biohaven Stock Zoomed More Than 6% Higher Today

News Why Biohaven Stock Dove by Nearly 20% on Thursday

News Why Biohaven Stock Plummeted by More Than 15% Today

News Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

News Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

News Why Biohaven Stock Triumphed on Tuesday

News Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study

News Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

News Biohaven GAAP EPS of -$0.88 misses by $0.04

SEC filing BHVN Reports $12M Q1 Revenue, $0.05 EPS, Updates Pipeline: Opakalim 2H26 Data, Taldefgrobep 2H26, BHV-1400/BHV-1300 Pivotal 2H26, BHV-1530 Escalation, 5 AAN Abstracts

SEC filing BHVN Votes For Directors Heffernan 76.1M Antonijevic 76.6M Hugin 76.6M Ratifies EY Auditors 123.7M Advisory Vote Compensation 87.5M Approved

News Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Insider trade Purchase by CHILDS JOHN W

Short volume Short volume 74% of volume (3.4σ)

News ClearBridge Small-Cap Growth trims Duolingo, Biohaven, QLYS; Adds PTGX, SSD, BETA, DYN in Q4

News CannaLean Biotechs Announces Positive Completion of First-in-Human Feasibility Study of Its Novel CBD-Based Lipid-Lowering Therapy

News CMS Transitional Pass-Through Payment (TPT) description for HCPCS code C1741 has been revised

News Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform

Get push alerts for BHVN

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS